Karen Anthony PhD, FHEA, PgCert
Senior Lecturer in Molecular Bioscience
Molecular Biosciences Research Group Lead
Postal address:
Faculty of Health and Society
University of Northampton
University Drive
Northampton
NN1 5PH
United Kingdom
Email: karen.anthony@northampton.ac.uk
Phone: +44 (0) 1604 89 3467

Biography

Karen studied biochemistry at the University of Leeds spending one year as a sandwich student at GlaxoSmithKline (GSK), Essex. At GSK Karen experienced the drug discovery process through performing large-scale purifications of protein drug targets. Developing a strong interest in neurodegeneration Karen joined the lab of Dr Jean-Marc Gallo at the Institute of Psychiatry, King's College London. Her PhD "tau RNA processing in neurodegeneration: *trans*-acting factors regulating alternative splicing and mRNA localisation" was awarded in 2009. As a post-doc in Dr Gallo's lab Karen established proof-of-concept for RNA reprogramming strategies including RNA *trans*-splicing therapies for spinocerebellar ataxia type 1 and the tauopathies. In 2010 Karen successfully translated her RNA expertise to the neuromuscular field and moved to the Dubowitz Neuromuscular Centre, Institute of Child Health, University College London (UCL). Working with Professor Francesco Muntoni, Karen played a key role in developing antisense oligonucleotide-mediated exon skipping as a therapeutic strategy for Duchenne muscular dystrophy (DMD). Her pre-clinical and clinical work in this area culminated in the first FDA-approved drug for DMD. In 2015 Karen attained a lectureship at the University of Northampton where she founded and leads the Molecular Biosciences Research Group. Her laboratory investigates the molecular mechanisms of neurological disorders with a focus on the neuropathophysiology of DMD. Karen also consults for international pharmaceutical and biotechnology companies on methodology for clinical trial biochemical outcome measures and the development of exon skipping and trans-splicing therapies. She is currently leading the the proof-of-concept and pre-clinical development of innovative trans-splicing applications for rare diseases.

Research outputs

A systematic literature review and meta-analysis of the effectiveness of vitamin D supplementation for patients with Duchenne muscular dystrophy
Guo, J. & Anthony, K., 15 Oct 2023, (E-pub ahead of print) In: Neuromuscular Disorders. 10 p.

T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy
Anthony, K., Ala, P., Catapano, F., Meng, J., Domingos, J., Perry, M., Ricotti, V., Maresh, K., Phillips, L., Servais, L., Seferian, A., De Lucia, S., de Groot, I., D Krom, Y., Verschuuren, JGM., Niks, E., Straub, V., Guglieri, M., Voit, T., Morgan, J., & 1 othersMuntoni, F., 1 Dec 2022, (E-pub ahead of print) In: Human Gene Therapy.

Evaluation of RNA trans-splicing as a therapeutic strategy for spinocerebellar ataxia type 1
Buijsen, R., Green, E., Avale, E., Gallo, J-M. & Anthony, K., 1 Nov 2022.

Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma
Naidoo, M., Jones, L., Conboy, B., Hamarneh, W., D'Souza, D., Anthony, K. & Machado, L., 5 Sept 2022. 1 p.

A Survey of Machine Learning Approaches Applied to Gene Expression Analysis for Cancer Prediction
Khalsan, M., Machado, L., SALIH AL-SHAMERY, EMAN., Ajit, S., Anthony, K., Mu, M. & Opoku Agyeman, M., 18 Mar 2022, In: IEEE Access.

Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma
Naidoo, M., Jones, L., Conboy, B., Hamarneh, W., D'Souza, D., Anthony, K. & Machado, L., 25 Feb 2022, In: Scientific Reports. 12, 1, 3200.

RNA-based therapeutics for neurological diseases
Anthony, K., 22 Jan 2022, In: RNA Biology. 19, 1, p. 176-190 15 p.

Outcomes of treatment of synovial sarcoma
Robertson-Smith, B., McCulloch, T., Campbell, J., Anthony, K. & Ashford, R., 8 Oct 2021.

Regulation of the alternative splicing of Dp71, the major brain dystrophin transcript, by splicing factors
Wood, C. & Anthony, K., 1 Oct 2021, In: Neuromuscular Disorders. 31, 1, p. S89-S90

The Duchenne muscular dystrophy gene and cancer
Jones, L., Naidoo, M., Machado, L. & Anthony, K., 14 Nov 2020, In: Cellular oncology (Dordrecht). 44, 1, p. 19-32 14 p.

Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Naidoo, M. & Anthony, K., 13 Dec 2019, (E-pub ahead of print) In: Molecular Neurobiology. 57, 3, p. 1748-1767 20 p.

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
Hiller, M., Falzarano, M. S., Garcia-Jimenez, I., Sardone, V., Verheul, R. C., Popplewell, L., Anthony, K., Ruiz-Del-Yerro, E., Osman, H., Goeman, J. J., Mamchaoui, K., Dickson, G., Ferlini, A., Muntoni, F., Aartsma-Rus, A., Arechavala-Gomeza, V., Datson, N. A. & Spitali, P., 2 Oct 2018, In: PLoS ONE. 13, 10, p. 1-15 15 p.

Neuropathophysiology of Duchenne muscular dystrophy: involvement of the dystrophin isoform Dp71 in cell migration and proliferation
Ash, A., Machado, L., Raleigh, S. M. & Anthony, K., 1 Apr 2018, In: Neuromuscular Disorders. 28, Sup. 1

Brain involvement in Duchenne muscular dystrophy: a role for dystrophin isoform Dp71 in cell migration and proliferation
Ash, A., Booth-Wynne, L. & Anthony, K., 2 Oct 2017, In: Neuromuscular Disorders. 27, Supp 2

Health and wellbeing amongst older people research in Northamptonshire
Poole, H., Sixsmith, J., Parkes, J., Ward, A., Pyer, M., Campbell, J., Machado, L., Rehling, T., Youell, J., Carter, J., Oyebode, J., O'Malley, M., Anthony, K., Rogers, S., Jones, J., Siddons, L., Smith, L-A., Kay, A. D., Fraser, M., Score, J., & 8 othersEl Khoury, L., Hameed, A., Albalbeisi, N., Durrant, L. G., Al-Zubaidi, R., Al-Rayahi, I., da Silva, K. & Taylor, J., 1 Aug 2017, (East Midlands Research into Ageing Network (EMRAN) Discussion Paper Series).

A UV cross-linking method combined with infrared imaging to analyse RNA–protein interactions
Malmqvist, T., Spickett, C., Gallo, J-M. & Anthony, K., 5 Jun 2017, In: Biology Methods & Protocols. 2, 1, p. 1-4 4 p., 1.

G.P.147 - Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant: implications for clinical trials
Ricotti, V., Eagle, M., Butler, J., Decostre, V., Deborah, R., Moraux, A., Anthony, K., Sleby, V., Guglieri, M., Van der Holst, M., Jansen, M., Morgan, J., de Groot, I., Niks, E., Verschuuren, J., Servais, L., Hogrel, J. Y., Voit, T., Straub, V. & Muntoni, F., 1 Oct 2015, In: Neuromuscular Disorders. 25, Supp 2

G.P.228 - Micro RNA profile associated with the dystrophin level in Becker muscular dystrophy
Zaharieva, I., Cirak, S., Anthony, K., Feng, L., Tasca, G., Ferlini, A., Morgan, J. & Muntoni, F., 1 Oct 2015, In: Neuromuscular Disorders. 25, Supp 2

Dystrophin quantification: biological and translational research implications
Anthony, K., Arechavala-Gomeza, V., Taylor, L. E., Vulin, A., Kaminoh, Y., Torelli, S., Feng, L., Janghra, N., Bonne, G., Beuvin, M., Barresi, R., Henderson, M., Laval, S., Lourbakos, A., Campion, G., Straub, V., Voit, T., Sewry, C. A., Morgan, J. E., Flanigan, K. M., & 1 othersMuntoni, F., 25 Nov 2014, In: Neurology. 83, 22, p. 2062-2069 8 p.

Tau mRNA is present in axonal RNA granules and is associated with elongation factor 1A
Malmqvist, T., Anthony, K. & Gallo, J-M., 10 Oct 2014, In: Brain Research. 1584, p. 22-27 6 p.

Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to Exon 44 or 45 skipping
Anthony, K., Arechavala-Gomeza, V., Ricotti, V., Torelli, S., Feng, L., Janghra, N., Tasca, G., Guglieri, M., Barresi, R., Armaroli, A., Ferlini, A., Bushby, K., Straub, V., Ricci, E., Sewry, C., Morgan, J. & Muntoni, F., 1 Jan 2014, In: JAMA Neurology. 71, 1, p. 32-40 9 p.

Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy
Anthony, K., Ricotti, V., Guglieri, M., Servais, L., Voit, T., Bushby, K., Straub, V., Morgan, J. & Muntoni, F., 28 Aug 2013, In: Neuromuscular Disorders.

A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice
Zhou, H., Janghra, N., Mitrpant, C., Dickinson, R. L., Anthony, K., Price, L., Eperon, I. C., Wilton, S. D., Morgan, J. & Muntoni, F., 21 Jan 2013, (E-pub ahead of print) In: Human Gene Therapy. 24, 3, p. 331-342 12 p.

Exon Skipping Quantification by Quantitative Reverse-Transcription Polymerase Chain Reaction in Duchenne Muscular Dystrophy Patients Treated with the Antisense Oligomer Eteplirsen
Anthony, K., Feng, L., Arechavala-Gomeza, V., Guglieri, M., Straub, V., Bushby, K., Cirak, S., Morgan, J. & Muntoni, F., Oct 2012, In: Human Gene Therapy Methods. p. 336-345 10 p.

Biochemical and clinical variability of Becker muscular dystrophy: Predicting optimal target exons for exon skipping therapy in Duchenne muscular
Anthony, K., Arechavala-Gomeza, V., Ricotti, V., Torelli, S., Feng, L., Tasca, G., Guglieri, M., Barresi, R., Armaroli, A., Ferlini, A., Bushby, K., Straub, V., Ricci, E., Sewry, C., Morgan, J. & Muntoni, F., 30 Aug 2012, In: Neuromuscular Disorders.

Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Arechavala-Gomeza, V., Anthony, K., Morgan, J. & Muntoni, F., 1 Jun 2012, In: Current Gene Therapy. p. 152-160 9 p.

Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in duchenne muscular dystrophy
Cirak, S., Feng, L., Anthony, K., Arechavala-Gomeza, V., Torelli, S., Sewry, C., Morgan, J. E. & Muntoni, F., 1 Feb 2012, In: Molecular Therapy. 20, 2, p. 462-467 6 p.

Exon-skipping therapy for Duchenne muscular dystrophy - Authors' reply
Arechavala-Gomeza, V., Cirak, S., Anthony, K., Morgan, J. & Muntoni, F., 14 Jan 2012, In: The Lancet.

A morpholino antisense oligonucleotide rescues type I and type III SMA mice
Zhou, H., Janghra, N., Anthony, K., Morgan, J. & Muntoni, F., 2012, In: Neuromuscular Disorders.

Correlation of internally deleted dystrophin and dystrophin-associated protein expression with clinical severity in Becker muscular dystrophy
Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomeza, V., Armaroli, A., Guglieri, M., Straathof, C. S., Verschuuren, J. J., Aartsma-Rus, A., Helderman-Van Den Enden, P., Bushby, K., Straub, V., Sewry, C., Ferlini, A., Ricci, E., Morgan, J. & Muntoni, F., 2012, In: Neuromuscular Disorders.

Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials
Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomeza, V., Armaroli, A., Guglieri, M., Straathof, C. S., Verschuuren, J. J., Aartsma-Rus, A., Helderman-Van Den Enden, P., Bushby, K., Straub, V., Sewry, C., Ferlini, A., Ricci, E., Morgan, J. E. & Muntoni, F., 18 Nov 2011, In: Brain. p. 3544-3556 13 p.

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., Dickson, G., Wood, M. J., Wilton, S. D., Straub, V., Kole, R., Shrewsbury, S. B., Sewry, C., Morgan, J. E., Bushby, K. & Muntoni, F., 13 Aug 2011, In: The Lancet. p. 595-605 11 p.

A TaqMan qRT-PCR assay to assess patient response in exon skipping clinical trials for Duchenne muscular dystrophy
Anthony, K., Feng, L., Arechavala-Gomeza, V., Morgan, J. & Muntoni, F., 2011.

Exon skipping and dystrophin restoration in Duchenne muscular dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Garralda, M. E., Wells, D. J., Dickson, G. , Wood, M. J., Wilton, S. D., Straub, V., Shrewsbury, S. B., Sewry, C., Morgan, J., Bushby, K. & Muntoni, F., 2011, In: Neuromuscular Disorders.

P07 The feasibility of exon skipping to restore the reading frame in DMD patients with duplications
kim, J., Anthony, K., cloke, V., yau, M., Abbs, S., Morgan, J. & Muntoni, F., 2011, In: Neuromuscular Disorders.

Quantification of exon skipping in Duchenne muscular dystrophy by qRT-PCR
Anthony, K., Morgan, J. & Muntoni, F., 2011, In: Neuromuscular Disorders.

Aberrant RNA processing events in neurological disorders
Anthony, K. & Gallo, J. M., 18 Jun 2010, In: Brain Research. p. 67-77 11 p.

Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing
Rodriguez-Martin, T., Anthony, K., Garcia-Blanco, M. A., Mansfield, S. G., Anderton, B. H. & Gallo, J. M., 2009, In: Human Molecular Genetics. p. 3266-3273 8 p.

Expression, localization and tau exon 10 splicing activity of the brain RNA-binding protein TNRC4
Chapple, P. J., Anthony, K., Martin, T. R., Dev, A., Cooper, T. A. & Gallo, J. M., 15 Nov 2007, In: Human Molecular Genetics. p. 2760-2769 10 p.

Characterization of the Neuronal RNA-binding Protein CELF3, a Modulator of Tau Exon 10 Alternative Splicing
Chapple, P. J., Rodriguez-Martin, T., Anthony, K., Cooper, T. A. & Gallo, J-M., 2007.

Identification of regulators of tau mRNA localisation
Anthony, K., Chapple, P. J. & Gallo, J-M., 2007.